News | August 17, 2025
AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease
Phase 1 dosing is expected to finish by the end of 2025
Phase 1 dosing is expected to finish by the end of 2025
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Medical plastics make up about 25 per cent of the 14,000 tons of waste generated daily in US healthcare facilities
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The conference will explore the path to India’s first billion-dollar drug, evolution towards value-based healthcare, biotech breakthroughs, and the role of AI and LLMs in care delivery
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Subscribe To Our Newsletter & Stay Updated
